Targets › DRD3
28 programs from 27 companies in 62 trials: 25 Phase 2, 22 Phase 3, 8 Phase 4, 7 Phase 1; Psychiatry, Neurology, Other; next expected readout Nov 2026.
G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P35462)
Open in Phaseline: the race on DRD3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Navamedic | Levodopa Dopamine D3 receptor agonist | DRD3 | Phase 4 | PARKINSON DISEASE (Disorder) | Mar 2027 |
| Dennis M. McNamara, MD, MS | Bromocriptine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 4 | Peripartum Cardiomyopathy, Postpartum | Jun 2028 |
| Massachusetts General Hospital | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 4 | Adrenoleukodystrophy | – |
| Jimma University | Bromocriptine mesylate D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Dilated Cardiomyopathy | Nov 2026 |
| Gedeon Richter | Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 3 | Schizophrenia; Depression, Bipolar; Bipolar I Disorder | Dec 2026 |
| NeuroDerm | Levodopa (ND0612) Dopamine D3 receptor agonist | DRD3 | Phase 3 | Parkinson's Disease; Freezing of Gait; Parkinson Disease; Acute Stroke … | Feb 2027 |
| AbbVie | Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 3 | Depression | Mar 2027 |
| LB Pharmaceuticals | LB-102 Atypical antipsychotic; dopamine D2/D3 receptor antagonist | DRD2, DRD3 | Phase 3 | Schizophrenia; Bipolar I Disorder | Jun 2027 |
| Daniel Lindqvist | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Bipolar Disorder (BD) | Dec 2029 |
| Shanghai Mental Health Center | Amisulpride Atypical antipsychotic; selective dopamine D2 and D3 receptor antagonist | DRD2, DRD3 | Phase 3 | Treatment-resistant Schizophrenia | Dec 2030 |
| MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Apomorphine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Idiopathic Parkinson's Disease | – |
| I.R.C.C.S. Fondazione Santa Lucia | Rotigotine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Alzheimer Disease | – |
| University of California, San Diego | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Anxiety Disorders | Nov 2026 |
| Bioprojet | BP1.4979 Selective dopamine D3 partial agonist | DRD3 | Phase 2 | Essential Tremor; Premature (Early) Ejaculation | Dec 2026 |
| University of Liege | Apomorphine Hydrochloride D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Disorder of Consciousness | Dec 2026 |
| M.D. Anderson Cancer Center | Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, DRD2, DRD3, DRD4 | Phase 2 | Delirium | Feb 2027 |
| M.D. Anderson Cancer Center | Haloperidol Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor inverse agonist | HTR2A, DRD2, DRD3, DRD4 | Phase 2 | Delirium; Advanced Malignant Neoplasm; Advanced Cancers | Feb 2027 |
| Instituto do Cancer do Estado de São Paulo | Amisulpride Dopamine D2 and D3 receptor antagonist | DRD2, DRD3 | Phase 2 | Post Operative Nausea and Vomiting (PONV) | Mar 2027 |
| Boryung Pharmaceutical | Olanzapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy … | May 2027 |
| Clinical Academic Center (2CA-Braga) | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Obsessive-Compulsive Disorder | Aug 2028 |
| University Hospital, Rouen | rotigotine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Kidney Diseases | Jul 2030 |
| Stanford University | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Depression - Major Depressive Disorder | Aug 2030 |
| Md. Moktadirul Hoque Shuvo | Trifluoperazine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Functional Dyspepsia | – |
| Mapi Pharma | Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 1 | Schizophrenia | Dec 2026 |
| Serina Therapeutics | SER-252 (PEOZ-apomorphine) Dopamine receptor agonist (D1-like and D2-like dopamine receptors) | DRD1, DRD2, DRD3, DRD4, DRD5 | Phase 1 | PARKINSON DISEASE (Disorder) | Jan 2027 |
| University of Pennsylvania | [18F]FTP D3 dopamine receptor radioligand for PET imaging | DRD3 | Phase 1 | D3 Dopamine Receptor | Jun 2027 |
| Anxo Pharmaceutical | AX251 LAI Dopamine D2/D3 receptor partial agonist | DRD2, DRD3 | Phase 1 | Schizophrenia | Jul 2028 |
| Capital Medical University | Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, DRD2, DRD3, DRD4 | Phase 1 | Acute Ischemic Stroke | – |
Schizophrenia (7) PARKINSON DISEASE (Disorder) (3) Delirium (3) Bipolar I Disorder (2) Advanced Malignant Solid Neoplasm (2) Multiple Myeloma (2) Parkinson's Disease (2) Essential Tremor (1) Premature (Early) Ejaculation (1) Depression, Bipolar (1) Advanced Malignant Neoplasm (1) Advanced Cancers (1)
small molecule (25), protein or peptide (2)
M.D. Anderson Cancer Center (2) LB Pharmaceuticals (1) Bioprojet (1) Gedeon Richter (1) Serina Therapeutics (1) Boryung Pharmaceutical (1) University of Liege (1) Md. Moktadirul Hoque Shuvo (1) Shanghai Mental Health Center (1) Anxo Pharmaceutical (1) Mapi Pharma (1) AbbVie (1) Daniel Lindqvist (1) Stanford University (1) Navamedic (1) University Hospital, Rouen (1) University of California, San Diego (1) Jimma University (1) NeuroDerm (1) University of Pennsylvania (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.